The current status of interventions aiming at reducing sudden cardiac death in dialysis patients

被引:32
作者
de Bie, Mihaly K. [1 ]
van Dam, Bastiaan [2 ]
Gaasbeek, Andre [3 ]
van Buren, Marjolijn
van Erven, Lieselot [1 ]
Bax, Jeroen J. [1 ]
Schalij, Martin J. [1 ]
Rabelink, Ton J. [3 ]
Jukema, J. Wouter [1 ]
机构
[1] Leiden Univ, Dept Cardiol C5 P, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Med Ctr Alkmaar, Dept Nephrol, Alkmaar, Netherlands
[3] Leiden Univ, Dept Nephrol, Med Ctr, NL-2300 RC Leiden, Netherlands
关键词
Sudden cardiac death; Dialysis; Implantable cardioverter defibrillator therapy; Ischaemic heart disease; Left ventricular hypertrophy; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; LEFT-VENTRICULAR HYPERTROPHY; ACUTE MYOCARDIAL-INFARCTION; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; MORTALITY RISK; HEART-FAILURE; SURVIVAL; IMPACT;
D O I
10.1093/eurheartj/ehp185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mortality in dialysis patients is extremely high, with an annual death rate of similar to 23%. Sudden cardiac death (SCD) is the single largest cause of death in dialysis patients accounting for similar to 60% of all cardiac deaths and 25% of all-cause mortality. Interventions aiming at reducing cardiovascular mortality, especially SCD, in dialysis patients are therefore extremely important and clinically highly relevant. The purpose of this review is to give an outline of the epidemiology of SCD in dialysis patients and to provide a comprehensive overview of several interventional strategies (medical therapies, changing dialysis modality, and revascularization). Furthermore, it will discuss the current knowledge regarding the value of preventive implantable cardioverter defibrillator implantation and address future implications of the interventional strategies mentioned.
引用
收藏
页码:1559 / 1564
页数:6
相关论文
共 70 条
[1]   β-Blocker use in long-term dialysis patients -: Association with hospitalized heart failure and mortality [J].
Abbott, KC ;
Trespalacios, FC ;
Agodoa, LY ;
Taylor, A ;
Bakris, GL .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (22) :2465-2471
[2]   Left ventricular hypertrophy in renal failure [J].
Amann, K ;
Rychlík, I ;
Miltenberger-Milteny, G ;
Ritz, E .
KIDNEY INTERNATIONAL, 1998, 54 :S78-S85
[3]  
Amann K, 1997, Adv Ren Replace Ther, V4, P212
[4]   Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? [J].
Amann, K ;
Buzello, M ;
Simonaviciene, A ;
Miltenberger-Miltenyi, G ;
Koch, A ;
Nabokov, A ;
Gross, ML ;
Gless, B ;
Mall, G ;
Ritz, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (07) :964-969
[5]  
[Anonymous], 2006, USRDS 2006 ANN DAT R
[6]  
[Anonymous], 2008, Am J Kidney Dis, V51, pS1
[7]  
Ansell D., 2007, UK RENAL REGISTRY RE
[8]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[9]  
Bardy GH, 2005, NEW ENGL J MED, V352, P2146
[10]   Characteristics of sudden death in hemodialysis patients [J].
Bleyer, A. J. ;
Hartman, J. ;
Brannon, P. C. ;
Reeves-Daniel, A. ;
Satko, S. G. ;
Russell, G. .
KIDNEY INTERNATIONAL, 2006, 69 (12) :2268-2273